Provide data update for the ARTACUS clinical trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Aug 2022
- Due
- 30 Jun 2023
- Delivered
- June 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company continues to enroll patients into its ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancers and expects to provide a data update in H1 2023.”
What we found
Evidence strength A What the grades mean
The company presented initial data from the ARTACUS clinical trial at the American Transplant Congress (ATC) meeting in June 2023, fulfilling the commitment to provide an update in H1 2023.
-
A Replimune Group, Inc. 8-K filed 2023-08-03
“Presented initial data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancers at the American Transplant Congress (ATC) Meeting in June.” ✓ confirmed on the page
-
A Replimune Group, Inc. 10-Q filed 2023-08-03
“As reported at the American Transplant Congress (ATC) Meeting in June 2023, the data demonstrated an ORR of 27.3%, with all responders achieving confirmed CR.” ✓ confirmed on the page
Market reaction: the shares moved -11.2% against the S&P 500 over the three sessions around the disclosure (2 Aug 2023 to 7 Aug 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Provide
- Deliverable
- ARTACUS clinical trial data update
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REPL-002684 · Corrections policy